Literature DB >> 32064090

Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome.

Maria de Castro Julve1, Paula Miralles Albors1, Sara Ortonobes Roig1, Roser Vives2, Luis Falgueras3, Mònica Gómez-Valent1.   

Abstract

Thiscase report concerns a 34-year-old male with a hip prosthesis infection, under treatment with antidepressant and antihypertensive drugs, who presented with an increase in blood pressure after four days of treatment with oral tedizolid. Tedizolid was discontinued, and the dose of antihypertensive was increased. The patient progressively achieved the normalisation of blood pressure values, which allowed a reduction in the antihypertensive agent dose to its usual regimen. No cases of hypertension or serotonin toxicity are described in the initial tedizolid studies, where patients treated with other serotonergic drugs were excluded. However, this does not mean that these effects may not occur in clinical practice, especially in patients under concomitant treatment with this type of medication, because of the greater risk of drug interactions. The causality of this suspected drug reaction was analysed and it was considered as possible. The case has been reported to the pharmacovigilance system. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adverse effects; hypertensive crisis; pharmacological interactions; serotonin syndrome; tedizolid

Year:  2018        PMID: 32064090      PMCID: PMC6992968          DOI: 10.1136/ejhpharm-2018-001752

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  9 in total

1.  Serotonin toxicity caused by the interaction of fentanyl and serotonergic medications.

Authors:  Melanie C Armitage; Kathryn I Woolfield; Colin B Page
Journal:  Emerg Med Australas       Date:  2015-12-17       Impact factor: 2.151

Review 2.  Serotonin syndrome: Preventing, recognizing, and treating it.

Authors:  Robert Z Wang; Vishal Vashistha; Sukhdeep Kaur; Nathan W Houchens
Journal:  Cleve Clin J Med       Date:  2016-11       Impact factor: 2.321

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Authors:  George G Zhanel; Riley Love; Heather Adam; Alyssa Golden; Sheryl Zelenitsky; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Andrew Walkty; Alfred S Gin; Matthew Gilmour; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 5.  Serotonin toxicity associated with the use of linezolid: a review of postmarketing data.

Authors:  Kenneth R Lawrence; May Adra; P Ken Gillman
Journal:  Clin Infect Dis       Date:  2006-04-27       Impact factor: 9.079

6.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

Review 8.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

9.  Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.

Authors:  Anna Rickli; Evangelia Liakoni; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.